What EcoR1 Capital, LLC reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1587114 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 7.9M |
| ±0% |
| $531.9M |
| 25.9% |
AKTSAktis Oncology, Inc. | 4.8M | New | $155.5M | 7.6% |
CGONCG Oncology, Inc. | 1.5M | +35.6% | $106.2M | 5.2% |
ETONEton Pharmaceuticals, Inc. | 2.2M | ±0% | $78.6M | 3.8% |
CRSPCRISPR Therapeutics AG | 1.4M | ±0% | $75.8M | 3.7% |
ORICOric Pharmaceuticals, Inc. | 6.7M | ±0% | $72.9M | 3.5% |
TRAXFirst Tracks Biotherapeutics, Inc. | 3.2M | New | $63.9M | 3.1% |
LKFTLakefront Biotherapeutics NV | 1.7M | ±0% | $50M | 2.4% |
NGNENeurogene Inc. | 1.3M | ±0% | $40M | 1.9% |
| 561.5K | New | $39.9M | 1.9% |
STOKStoke Therapeutics, Inc. | 735K | +635.0% | $24M | 1.2% |
FULCFulcrum Therapeutics, Inc. | 6.5M | New | $24M | 1.2% |
LEGNLegend Biotech Corp | 800K | New | $23.1M | 1.1% |
BBOTBridgeBio Oncology Therapeutics, Inc. | 2.8M | ±0% | $21.5M | 1% |
MBXMBX Biosciences, Inc. | 388.5K | −50.0% | $21.4M | 1% |
ZBIOZenas BioPharma, Inc. | 789.5K | ±0% | $20M | 1% |
ATRAAtara Biotherapeutics, Inc. | 1.6M | +1,458.3% | $17.8M | 0.9% |
RLAYRelay Therapeutics, Inc. | 697.9K | −63.4% | $13.1M | 0.6% |
AURAAura Biosciences, Inc. | 1.7M | New | $11.8M | 0.6% |
ODTXOdyssey Therapeutics, Inc. | 555.6K | New | $10.4M | 0.5% |
EIKNEikon Therapeutics, Inc. | 732.6K | New | $9.6M | 0.5% |
PHVSPharvaris N.V. | 235K | New | $8.1M | 0.4% |
ZURAZura Bio Ltd | 1.2M | ±0% | $7M | 0.3% |
PHATPhathom Pharmaceuticals, Inc. | 625K | ±0% | $6.8M | 0.3% |
NRIXNurix Therapeutics, Inc. | 270K | New | $6.6M | 0.3% |
ERASErasca, Inc. | 330K | −63.3% | $6M | 0.3% |
ELOXEloxx Pharmaceuticals, Inc. | 400K | New | $5.6M | 0.3% |
AARDAardvark Therapeutics, Inc. | 396.2K | New | $2.3M | 0.1% |
HLXCHelix Acquisition Corp. III | 200K | New | $2.1M | 0.1% |
MREOMereo BioPharma Group plc | 1M | −92.5% | $317.7K | 0.1% |
SRZNWSurrozen, Inc. | 4.4K | ±0% | $115.3K | 0.1% |
| 14.7K | New | $84.7K | 0.1% |
